-
Mashup Score: 0Donanemab in Early Alzheimer’s Disease | NEJM - 3 year(s) ago
Original Article from The New England Journal of Medicine — Donanemab in Early Alzheimer’s Disease
Source: New England Journal of MedicineCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0Donanemab Slows Rate of Cognitive Decline in Early Symptomatic Alzheimer Disease - Practical Neurology - 3 year(s) ago
In the phase 2 TRAILBLAZER-ALZ (NCT03367403) study, donanemab (LY3002813; Lilly and Company, Indianapoliz, IN) reduced cognitive decline in individual
Source: Practical NeurologyCategories: Latest Headlines, NeurologyTweet-
#Donanemab Slows Rate of #CognitiveDecline in Early Symptomatic Alzheimer Disease @LillyPad #AD #neurology #PracticalNeurology https://t.co/XMbNjJ7k27
-
-
Mashup Score: 0Wolters Kluwer Health - 3 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…
Source: journals.lww.comCategories: Latest Headlines, NeurologyTweet-
In patients with early symptomatic #Alzheimersdisease, #donanemab, a humanized monoclonal antibody, slowed #cognitive decline and functional dysfunction. #neurology https://t.co/OksDusgPXm https://t.co/dAAk7qSLFV
-
-
Mashup Score: 2Eli Lilly adds $23B in market cap as investors rush on promise that this will be the amyloid Alzheimer's drug that works - 3 year(s) ago
It’s been decades and dozens of drugs, and most of them failed, but the amyloid hypothesis won’t go gently into the night. While the world awaits the FDA’s decision on Biogen’s controversial aducanumab pitch, a Big Pharma rival says they now have data to support their own amyloid-clearing Alzheimer’s drug.
Source: Endpoints NewsCategories: Healthcare Professionals, Latest HeadlinesTweet-
Eli Lilly adds $23B in market cap as investors rush on promise that this will be the amyloid #Alzheimer's drug that works. #donanemab https://t.co/ndMiFrhFp2 #donanemab
-
In patients with early Alzheimer’s disease, #donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed. https://t.co/mL1YMN9wLt https://t.co/grAjlQmllZ